Researcher
Lisa F.P. Ng obtained her PhD in molecular virology in coronaviruses from the National University of Singapore (NUS) in 2002. After joining the A*STAR Genome Institute of Singapore (A*STAR GIS) in 2002 as a Postdoctoral Fellow, she worked on viral diseases such as hepatitis, severe acute respiratory syndrome and influenza. Ng is currently the Executive Director at A*STAR Infectious Diseases Labs (A*STAR IDL) where she focuses on the immune responses to arthritic arboviruses that are epidemic or highly endemic in the tropical region. Ng has won numerous accolades for her research, including the ASEAN ‘International Young Scientist and Technologist Award’ in 2008 and A*STAR’s ‘Most Inspiring Mentor Award’ in March 2013.
Related Articles
Mosquitoes share the blame
16 Jul 2026A molecule found in Aedes mosquito saliva modulates the host body’s immune response during chikungunya
Immune crosstalk fuels viral flames
5 Feb 2025A*STAR researchers find that ordinary communications between immune cells during chikungunya virus infection can drive
Virus killers get under the skin
10 May 2024Research suggests monitoring individuals previously infected with Zika virus for chronic skin diseases caused by
Predicting persistence, and a glimmer of hope
31 Jan 2024A two-year study uncovers potential immune biomarkers to detect long COVID, and evidence that its
Mixed shots hit a moving target
19 Jan 2024While the new Omicron XBB COVID-19 subvariant deftly dodges immune defences even in vaccinated individuals,
What’s behind the rise of mpox?
12 Jul 2023Scientists survey how the mpox virus spreads through populations, the immunology of infections and current
Spotting the mechanisms of COVID-19 organ damage
4 Jul 2023A novel tissue-profiling approach provides new insights into the mechanisms of fatal COVID-19 by analysing
Breakthrough infections from a memory lapse
22 Mar 2023Vaccinated people affected by COVID-19 variants have different memory B cell responses than their close
How variants have loosened their grip
2 Dec 2022A deletion in the genome of SARS-CoV-2 variants makes resulting infections milder and could also
Why remdesivir works for some COVID-19 patients but not others
23 Jun 2022Remdesivir treatment is more likely to be successful in COVID-19 patients who are naturally able
A COVID-19 test as good as gold
3 Jun 2022A*STAR researchers create a next-generation, ultrasensitive COVID-19 rapid test powered by gold nanoparticles.
Tanzania’s feverish five revealed
21 Jan 2022During the 2018 outbreak in Southeastern Tanzania, there were four dengue virus serotypes and the
Immune secrets of the symptom-free
26 Nov 2021Unique immune responses shield some COVID-19 patients from the disease’s worst effects.
Cracking the code of long COVID
5 Nov 2021Elevated levels of inflammatory factors may be linked to persistent COVID-19 symptoms, researchers find.
SARS-CoV-2 antibodies hold out against variants
4 Oct 2021Data shows that antibodies produced as part of the COVID-19 immune response can neutralize a
How long do COVID-19 antibodies last?
9 Aug 2021The amount of neutralizing antibodies produced by COVID-19 patients—and the length of time they remain
Figuring out one fever from another
30 Jun 2021A*STAR researchers identified immune markers that can distinguish between common febrile diseases in Saudi Arabia.
Picking peptides for COVID tests
21 May 2021Four newly discovered SARS-CoV-2 peptides not only promise to make COVID-19 tests cheaper and more
Zika’s art of camouflage
21 Apr 2021The mosquito-borne virus dodges immune clearance by cloaking itself in disarmed antibodies.
Reducing uncertainty about COVID-19
11 Jan 2021A multifaceted study by the Singapore 2019 Novel Coronavirus Outbreak Research team is filling in
Predicting severe cases of COVID-19
28 Dec 2020A*STAR researchers identify new, specific markers of severe COVID-19 that may improve the management and
To control outbreaks, go back to basics
28 Aug 2020Two coronavirus experts suggest that the best way to control an outbreak may be to
The mutation making COVID-19 milder
24 Aug 2020Scientists at A*STAR have found that a mutation in SARS-CoV-2 called ∆382 leads to milder
The COVID-19 outliers
16 Jul 2020An international genetics consortium seeks to unravel the mystery of why COVID-19 infection is silent
Getting the SARS-CoV-2 antibody response straight
29 Jun 2020Two linear peptides identified by A*STAR researchers on the SARS-CoV-2 spike protein may improve the
What we know about COVID-19 and how it can be treated
14 May 2020Lisa F. P. Ng, a leading infectious disease expert on infection and immunity, shares how
How to maim a virus without killing it
7 Nov 2019Targeted mutagenesis is being used to create live-attenuated vaccines against the chikungunya virus.
Finding the ‘fingerprints’ of the Zika virus
19 Aug 2019A*STAR researchers have identified four peptide sequences that distinguish the Zika virus from other flaviviruses,
Revisiting the antiviral role of Viperin
19 Aug 2019The antiviral protein Viperin keeps immune cells in check to prevent joint swelling during chikungunya
The coincidental complications of coinfection
17 Apr 2019Malaria infections may be masking the extent of the emerging chikungunya epidemic



